Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells. Cell viability was evaluated by trypan-blue exclusion. Western blotting determined caspase and histone deacetylase activities and expression of poly(ADP)-ribose polymerase. Induction of apoptosis was identified by Hoechst staining, DNA electrophoresis, DNA hypoploidy and cell cycle phase analysis, and measurement of mitochondrial membrane potential. Subcellular translocation of apoptosis inducing factor and caspase-activated DNase after treatment was determined by confocal microscopy following immunofluorescent staining. VPA treatment increased apoptotic death of KAT-18 cells. VPA treatment was also associated with degradation of procaspase-3, procaspase-7, and poly(ADP)-ribose polymerase; induction of histone hyperacetylation; condensation of peripheral chromatin; decreased mitochondrial membrane potential and DNA content; and decreased translocation of apoptosis inducing factor and caspase-activated DNase. VPA in combination with doxorubicin, HS-1200, or lactacystin, applied at the highest concentrations that did not induce KAT-18 cell death, efficiently induced apoptosis in KAT-18 cells. The results suggest VPA combination therapy may represent an alternative therapeutic strategy for anaplastic thyroid carcinoma.
Kim
Tae Hyun
TH
Department of Anatomy and Cell Biology, Dong-A University College of Medicine, Busan 602-714, Korea.
Yoo
Young Hyun
YH
Kang
Do-Young
DY
Suh
Hongsuk
H
Park
Moon Ki
MK
Park
Ki-Jae
KJ
Kim
Sung-Heun
SH
D000111:Acetylcysteine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma / Q000188:drug therapy*; D002470:Cell Survival / Q000187:drug effects; D002635:Chenodeoxycholic Acid / Q000031:analogs & derivatives* / Q000138:chemical synthesis; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000008:administration & dosage*; D004353:Drug Evaluation, Preclinical; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000187:drug effects / Q000502:physiology; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured; D014635:Valproic Acid / Q000008:administration & dosage* / Q000494:pharmacology
D056572:Histone Deacetylase Inhibitors; D002635:Chenodeoxycholic Acid; C067713:lactacystin; D014635:Valproic Acid; D004317:Doxorubicin; D006655:Histone Deacetylases; D000111:Acetylcysteine